title: Primary cutaneous aggressive epidermotropic CD8+ T cell lymphoma with a chronic and indolent course. Is this different from peripheral T cell lymphoma?
abstract: Cutaneous T cell lymphomas most commonly have a CD4+ memory T cell phenotype and exhibit a relatively indolent course, but may in rare cases present with a CD8+ cytotoxic phenotype with a strikingly more aggressive clinical behavior. Primary cutaneous aggressive epidermotropic CD8+ T cell lymphoma is an extremely rare entity with distinct clinicopatological features. The clinical features and prognosis of the recently-described CD8+ peripheral lymphoma are very different from cytotoxic CD8+ epidermotropic lymphoma, but the histological and phenotypic characteristics are very similar. We report a new case of CD8+ epidermotropic lymphoma with a chronic course and suggest the possibility of an overlap between these two types of lymphoma.
authors.affiliation: Department of Dermatology, Hospital Municipal de Badalona, Barcelona, Spain.
authors.forename: Mercedes
authors.initials: M
authors.lastname: Gomez Vazquez
authors.forename: Ramón
authors.initials: R
authors.lastname: Navarra Amayuelas
mesh_terms: D000368:Aged; D015703:Antigens, CD / Q000032:analysis / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis / Q000276:immunology; D016410:Lymphoma, T-Cell, Cutaneous / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology / Q000532:radiotherapy; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis / Q000276:immunology; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000276:immunology; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology / Q000532:radiotherapy; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D015703:Antigens, CD; D019394:Ki-67 Antigen; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone